Is La Jolla Pharmaceutical Company (LJPC) Going to Burn These Hedge Funds?
A whopping number of 13F filings filed with U.S.
La Jolla Pharmaceutical Co (LJPC)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 0 | $0 | -100% | 0% |
| 2. | Schonfeld Strategic Advisors Ryan Tolkin (Cio) | 0 | $0 | -100% | 0% |
| 3. | D E Shaw D. E. Shaw | 0 | $0 | -100% | 0% |
| 4. | Millennium Management Israel Englander | 0 | $0 | -100% | 0% |
| 5. | Tang Capital Management Kevin C. Tang | 0 | $0 | -100% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.87 | 3,000 | Director | 100,000 | 2021-12-06 | Filing | |
| $3.84 | 1,000 | Director | 97,000 | 2021-12-06 | Filing | |
| $3.82 | 2,215 | Director | 96,000 | 2021-12-06 | Filing | |
| $3.81 | 1,000 | Director | 93,785 | 2021-12-06 | Filing | |
| $3.80 | 1,000 | Director | 92,785 | 2021-12-06 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.66 | 41,290 | Large Shareholder, Director | 9,607,934 | 2021-12-01 | Filing | |
| $3.76 | 136,255 | Large Shareholder, Director | 9,649,224 | 2021-12-01 | Filing | |
| $3.95 | 63,745 | Large Shareholder, Director | 9,785,479 | 2021-11-30 | Filing | |
| $3.95 | 6,597 | Large Shareholder, Director | 9,849,224 | 2021-11-30 | Filing | |
| $4.10 | 193,403 | Large Shareholder, Director | 9,855,821 | 2021-11-29 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 0 | $0 | 0% | |
| 2. | 0 | $0 | 0% | |
| 3. | 0 | $0 | 0% | |
| 4. | 0 | $0 | 0% | |
| 5. | 0 | $0 | 0% |
News See All
Do Hedge Funds Love La Jolla Pharmaceutical Company (LJPC)?
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September.
Is La Jolla Pharmaceutical Company (LJPC) Going to Burn These Hedge Funds?
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first.
Is La Jolla Pharmaceutical Company (LJPC) A Good Stock To Buy?
The market has been volatile in the last few months as the Federal Reserve finalized its rate cuts and uncertainty looms over trade negotiations with China.
La Jolla Pharmaceutical Company (LJPC): Hedge Funds In Wait-and-See Mode
The financial regulations require hedge funds and wealthy investors that crossed the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter.
Hedge Fund and Insider Trading News: Carl Icahn, Crispin Odey, ValueAct Capital, La Jolla Pharmaceutical (LJPC), New Mountain Finance Corp. (NMFC), and More
Billionaire activist investor Carl Icahn is building a stake in casino company Caesars Entertainment, sources familiar with the situation said. The size of Icahn’s stake is not immediately known.
Hedge Funds Are Crazy About La Jolla Pharmaceutical Company (LJPC)
There are several ways to beat the market, and investing in small cap stocks has historically been one of them.
Hedge Fund and Insider Trading News: Starboard Value LP, York Capital Management, Prospect Capital Corporation (PSEC), CytomX Therapeutics Inc (CTMX), Ichor Holdings Ltd (ICHR), and More
(Reuters) - Four of Starboard Value’s nominees to Newell Brands Inc’s (NWL.N) board of directors withdrew their nominations, a day after the company rebuffed the activist hedge fund’s challenge ...
13D Filing: Tang Capital Partners LP and La Jolla Pharmaceutical Co (LJPC)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240...
13D Filing: Tang Capital Partners LP and La Jolla Pharmaceutical Co (LJPC)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240...